Global generics industry continues fight for equal footing with R and D sector at ICH
This article was originally published in SRA
Executive Summary
The global generics industry is continuing its fight to achieve parity with the research-based pharmaceutical industry at the International Conference on Harmonisation, protesting that it refuses to be relegated to the side lines in the key global drug development standards and guidelines initiative1.
You may also be interested in...
'Historical Moment' As Global Generics Body Gets Seat On ICH Management Committee
The move recognizes the expertise that generic and biosimilar drug developers can bring to the scientific discussions at the International Council on Harmonisation.
'Historical Moment' As Global Generics Body Gets Seat On ICH Management Committee
The move recognizes the expertise that generic and biosimilar drug developers can bring to the scientific discussions at the International Council on Harmonisation.
COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: